Taysha Gene Therapies
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $1,986 | $2,302 | $2,022 | $1,788 |
Gross Profit | 1,709 | 2,302 | 2,022 | 1,788 |
EBITDA | -26,753 | -21,227 | -18,459 | -25,206 |
EBIT | -27,030 | -21,510 | -18,763 | -25,500 |
Net Income | -26,882 | -21,529 | -18,785 | -25,524 |
Net Change In Cash | 1,986 | 2,302 | 2,022 | 1,788 |
Free Cash Flow | -20,184 | -22,398 | -18,306 | -21,650 |
Cash | 312,761 | 116,593 | 139,036 | 157,688 |
Basic Shares | 297,988 | 269,306 | 250,134 | 267,824 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $8,333 | $15,451 | $2,502 | $0 |
Gross Profit | 8,333 | 15,451 | 2,502 | -492 |
EBITDA | -87,951 | -105,197 | -159,729 | -172,775 |
EBIT | -89,196 | -106,568 | -162,216 | -173,267 |
Net Income | -89,298 | -111,566 | -166,014 | -175,459 |
Net Change In Cash | 8,333 | 15,451 | 2,502 | 0 |
Free Cash Flow | -81,599 | -80,387 | -113,259 | -138,596 |
Cash | 139,036 | 143,940 | 87,880 | 149,103 |
Basic Shares | 250,134 | 232,242 | 175,808 | 150,602 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.08 |
2025-03-31 | -$0.07 |
2024-12-31 | -$0.07 |
